HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oxybenzone Sunscreen Remains Live Issue As Florida Lawmakers Lay Groundwork For 2020

Executive Summary

Florida's legislature does not reconvene until mid-January 2020, but interim committee meetings are in progress and a proposed bill to ban non-prescription sales of oxybenzone/octinoxate-containing sunscreens already has been filed for consideration in the next session.

You may also be interested in...



Florida Preemption Bill Poised To Undo Key West Sunscreen Ban

Headed for its second reading in the Florida House after its counterpart passed the Senate on 29 January, HB 113 would expressly preempt local regulation of OTC drugs and cosmetics. According to House analysis documents, “This nullifies the current City of Key West ordinance” banning the sale of sunscreens containing reputed coral-killing UV filters.

Cosmetics Market In 2019: CBD, Microplastic And US Sunscreen Uncertainty Among Year’s Biggest Issues

The opportunity represented by cannabidiol, and the uncertain future for commonly used sunscreen active ingredients in the US and microplastic in the EU, were issues of high interest among cosmetics industry stakeholders in 2019.

National Toxicology Program: Oxybenzone Shows ‘Equivocal Evidence Of Carcinogenic Activity’

A National Toxicology Program rat study linking oxybenzone to “equivocal evidence of carcinogenic activity” is far from damning, but it's a reminder of just how steep a mountain industry may have to climb to maintain the UV filter’s generally recognized as safe and effective (GRASE) status for OTC marketability, currently under FDA review.

Related Content

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel